VanEck Israel ETF (ISRA) is an exchange-traded fund that seeks to replicate as closely as possible the price and yield performance of the MVIS Israel Index, which tracks the performance of the most liquid Israeli companies listed on exchanges around the world. The fund invests primarily in Israeli equities across various sectors, including technology, industrials, healthcare, financials, and materials; key holdings typically feature prominent Israeli firms such as NICE Ltd., Check Point Software Technologies Ltd., and Teva Pharmaceutical Industries Ltd. ISRA provides investors with targeted exposure to Israel's innovative economy, emphasizing high-growth companies in cybersecurity, software, biotechnology, and defense-related technologies.
Launched in 2013 by VanEck, a New York-based asset manager founded in 1955 with global operations headquartered in the United States, the ETF primarily serves institutional and retail investors seeking emerging market opportunities in the Middle East. Geographically, it focuses on Israeli-domiciled or Israel-linked companies trading on U.S., Israeli, or other international exchanges, with no direct operations outside investment management. The fund employs a passive, full-replication strategy, holding all index constituents weighted by market capitalization, adjusted for free float and liquidity criteria.
Recent developments include portfolio rebalancing in response to market shifts, such as increased weighting toward technology amid Israel's tech sector boom post-2023; no major acquisitions, partnerships, or structural changes reported in the last 1-2 years, though VanEck has expanded its thematic ETF lineup with complementary products like the VanEck Semiconductor ETF. As of late 2025, assets under management remain stable around $100 million, reflecting steady interest in Israeli equities despite geopolitical tensions.